Ritedose expands BFS capacity for ophthalmic and respiratory medications

The Ritedose Corporation is expanding its sterile Blow-Fill-Seal (BFS) production capabilities at its Columbia, SC facility, adding 180-million-unit dose capacity for ophthalmic and respiratory medications. The new equipment is expected to begin production in August 2024.

“Ritedose has expanded its sterile Blow-Fill-Seal (BFS) capabilities, and the new equipment is expected to begin production in August of this year.”prnewswire.com

• 1 source
• prnewswire.comRitedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory MedicationsRitedoseJun 20, 2024

Summarized from public sources; check the original articles before acting on it.